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Abstract. A novel synthetic compound 6-acetyl-9-(3,4,5-
trimetho xybenzyl)-9H-pyrido[2,3-b]indole (HAC-Y6) 
demonstrated selective anticancer activity. In the present study, 
COLO 205 cells were treated with HAC-Y6 to investigate 
the molecular mechanisms underlying its effects. HAC-Y6 
induced growth inhibition, G2/M arrest and apoptosis in 
COLO 205 cells with an IC50 of 0.52±0.035 µM. Annexin V/PI 
double staining demonstrated the presence of apoptotic cells. 
JC-1 staining analysis showed that HAC-Y6 decreased mito-
chondrial membrane potential in support of apoptosis. An 
immunostaining assay revealed that HAC-Y6 depolymerized 
microtubules. Treatment of COLO 205 cells with HAC-Y6 
resulted in increased expression of BubR1 and cyclin B1 
and decreased expression of aurora A, phospho-aurora A, 
aurora B, phospho-aurora B and phospho-H3. HAC-Y6 treat-
ment increased protein levels of active caspase-3, caspase-9, 
Endo G, AIF, Apaf-1, cytochrome c and Bax, but treatment 
with the compound caused reduced levels of procaspase-3, 
procaspase-9, Bcl-xL and Bcl-2. Overall, our results suggest 
that HAC-Y6 exerts anticancer effects by disrupting micro-
tubule assembly and inducing G2/M arrest, polyploidy and 
apoptosis via mitochondrial pathways in COLO 205 cells.
Introduction
Colorectal cancer is the third most commonly diagnosed cancer 
in men and the second in women, with over 1.2 million new 
cancer cases and 608,700 deaths estimated to have occurred 
worldwide in 2008 (1). Colorectal cancer is a multistep process, 
involving progressive disruption of intestinal epithelium 
growth (2). The disease arises as a result of the accumulation 
of genetic errors, many of which affect the control of apoptosis 
(3). Clinical treatment options for colorectal cancer consist of 
surgery, radiation and chemotherapy, but these treatments are 
often unsatisfactory (4).
Previous studies have reported that heat shock protein 
90 (HSP90) inhibitors possess significant antitumor activity 
(5). HSP90 plays an essential role as a molecular chaperone, 
assisting in the correct folding of nascent and stress-accumulated 
misfolded proteins and preventing their aggregation (6). High 
HSP expression is a property of, and essential for the survival 
of, most cancers. Neutralizing HSPs could, thus, provide an 
alternative strategy for anticancer therapy (7).
Induction of cell cycle arrest and apoptosis are also potential 
strategies for cancer treatment. Investigators have widely explored 
the process of the cell cycle, particularly the CDK1/cyclin B1 
complex, which plays an important role in the regulation of 
the G2/M phase. During pro-metaphase, spindle-assembly 
checkpoint proteins, such as BubR1, prevent anaphase and 
mitotic exit (8,9). Anti-mitotic drugs that target microtubules 
have potential clinical application (10). Several studies have 
determined that microtubule-targeting agents act primarily to 
suppress spindle-microtubule dynamics, resulting in a blockade 
of metaphase/anaphase transition and the triggering of apoptotic 
cell death (11). The aurora kinase family is a collection of closely 
related serine/threonine kinases that are key regulators of mitosis 
(12,13). Fu et al demonstrated upregulated aurora kinase expres-
sion and activity in cancer cells, indicating that aurora kinase 
might serve as a useful target for therapy (14). Three related 
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aurora kinases have evolved in mammalian cells: aurora A, 
aurora B, and aurora C (13,15-18). Inhibition of aurora A or 
aurora B activity in tumor cells results in impaired chromosome 
alignment, abrogation of the mitotic checkpoint, polyploidy and 
subsequent cell death (12,19,20). Apoptosis is a mechanism by 
which cells undergo programmed death to control cell prolifera-
tion or in response to DNA damage (21). Biochemical features 
of apoptosis include DNA fragmentation, protein cleavage at 
specific locations, increased mitochondrial membrane perme-
ability and the appearance of phosphatidylserine (PS) on the cell 
membrane surface (22). The induction of apoptosis has formed 
the basis of several previous research investigations that focused 
on the selective killing of cancer cells (23).
Carbazole alkaloids are well-known natural compounds, 
some of which display anticancer activity (24-26). The 
β-carboline alkaloids occurring in medicinal plants have gained 
attention because of their antitumor effects (27). However, 
research on the anticancer activity of α-carboline (isostere of 
β-carboline) derivatives is relatively limited. In a prior investi-
gation, we synthesized a series of α-carboline derivatives and 
identified several of them as novel anticancer agents. Among 
these, 6-acetyl-9-(3,4,5-trimethoxybenzyl)-9H-pyrido[2,3-b]
indole (HAC-Y6) (Fig. 1) was the most potent. In the present 
study, HAC-Y6 was selected as a target compound and submitted 
to the National Cancer Institute (NCI, Bethesda, MD, USA) 
for further screening against a panel of 60 human tumor cell 
lines. Results indicated that HAC-Y6 is a promising anti-colon 
cancer agent. Further investigations of the molecular mecha-
nisms of HAC-Y6's anti-human colon carcinoma effects, using 
COLO 205 cells as a model, were performed, and our results are 
presented here.
Materials and methods
Chemicals and reagents. HAC-Y6 was synthesized in the labo-
ratory of the Graduate Institute of Pharmaceutical Chemistry, 
China Medical University (Taichung, Taiwan, R.O.C.). MTT 
(3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide), 
Hoechst 33258, propidium iodide (PI), Tris-HC1, Triton X-100, 
and RNase A were purchased from Sigma Chemical Co. 
(St. Louis, MO, USA). RPMI-1640 medium, L-glutamine, fetal 
bovine serum, penicillin-streptomycin, and trypsin-EDTA were 
obtained from Invitrogen Corp (Carlsbad, CA, USA). Antibodies 
for AIF, Apaf-1, aurora A, aurora B, phospho-aurora A, 
phospho-aurora B, Bcl-xL, BubR1, caspase-9, caspase-3, Endo G, 
phospho-H3, α-tubulin, β-tubulin, and poly(ADP-ribose) poly-
merase (PARP) were purchased from Cell Signaling Technology 
(Beverly, MA, USA). Antibodies for β-actin, Bax, Bcl-2, cyclin B1, 
CDK1, cytochrome c, horseradish peroxidase (HRP)-linked 
goat anti-mouse IgG, and goat anti-rabbit IgG were purchased 
from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The 
Annexin V-FITC Apoptosis Detection kit was obtained from 
Strong Biotech Corporation (Taipei, Taiwan, R.O.C.). The Flow 
Cytometry Mitochondrial Membrane Potential Detection kit 
was obtained from BD Biosciences (Los Angeles, CA, USA).
Cell culture. The human colon cancer cell line COLO 205 was 
obtained from the Food Industry Research and Development 
Institute (Hsinchu, Taiwan, R.O.C.). Cells were seeded into plates 
or dishes in RPMI-1640 medium supplemented with 10% fetal 
bovine serum, L-glutamine, 100 U/ml penicillin and 100 µg/ml 
streptomycin in a humid atmosphere of 5% CO2 and 95% air at 
37˚C. Cells were plated at a density of 2.5x104 cells per well in 
96-well plates for the cell viability assay, 1x105 cells per well 
in 24-well plates with cover slips for Hoechst staining, 2x105 
cells per well in 12-well plates for cell cycle assay, 1x106 cells 
per well in 6-well plates for mitochondrial membrane potential 
assay, and 1x107 cells per plate in 10 cm dishes for western blot 
analysis. Cells were allowed to adhere for 24 h before use.
Cell morphology. COLO 205 cells were plated at a density of 
2.5x105 cells per well in 12-well plates and then incubated with 
0.5 µM of HAC-Y6 for 24 to 72 h. Cells were directly examined 
and photographed under a phase contrast microscope.
Evaluation of cell viability using the MTT assay. COLO 205 
cells were plated at a density of 2.5x104 cells per well in 96-well 
plates, and cell survival was evaluated using MTT reduction 
assays. The reduction status of the cells was measured by a colori-
metric assay, indicating cell survival (28). MTT was dissolved in 
phosphate-buffered saline (PBS, 500 ml contains 137 mM NaCl, 
2.7 mM KCl, 4.3 mM Na2HPO4, 1.47 mM KH2PO4, pH 7.4) at 
a concentration of 1 mg/ml and filtered. After 48 h exposure to 
HAC-Y6, 50 µl MTT was added to each well and incubated for 
2 h at 37˚C in the dark. When absorbed by living cells, MTT 
is converted to a water-insoluble blue product (formazan). The 
formazan product was dissolved by adding 150 µl dimethylsulf-
oxide (DMSO) to each well. The absorption value at 570 nm was 
determined using an ELISA plate reader. Data are presented 
as the percentage of survival relative to vehicle-treated control 
culture. All measurements were performed in triplicate and each 
experiment was repeated at least three times.
Hoechst 33258 staining. Nuclei were stained with Hoechst 
33258 (bis-benzimide, Sigma) to detect chromatin condensa-
tion or nuclear fragmentation, morphological characteristics of 
apoptosis. HAC-Y6 treatment cells were stained with 5 µg/ml 
Hoechst 33258 for 10 min. After washing twice with PBS, cells 
were fixed with 4% paraformaldehyde (PFA) in PBS for 10 min 
at 25˚C. Fluorescence of the soluble DNA (apoptotic) fragments 
was measured in a Varian Fluorometer at an excitation wave-
length of 365 nm and emission wavelength of 460 nm.
Figure 1. Chemical structure of HAC-Y6.
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Flow cytometric analysis for cell cycle effects. Cells were fixed 
in 70% ethanol overnight and re-suspended in PBS containing 
20 µg/ml PI, 0.2 mg/ml RNase A, and 0.1% Triton X-100 
in a dark room. After 30 min incubation at 37˚C, cell cycle 
distribution was analyzed using ModFit LT Software (Verity 
Software House, Topsham, ME, USA) in a BD FACSCanto 
flow cytometer (Becton-Dickinson, San Jose, CA, USA).
Quantification of apoptosis. COLO 205 cells (2x105 cells/well) 
were fluorescently labeled for detection of apoptotic and 
necrotic cells by adding 100 µl of binding buffer, 2 µl of 
Annexin V-FITC, and 2 µl of PI to each sample. Samples were 
mixed gently and incubated at room temperature in the dark 
for 15 min. Binding buffer (300 µl) was added to each sample 
immediately before flow cytometric analysis. A minimum of 
10,000 cells within the gated region were analyzed.
Mitochondrial membrane potential analysis. Cells were plated 
on 6-well at 1.0x106 cells/well and treated with 1 µM HAC-Y6 
for 6-24 h. Mitochondrial membranes were stained with 0.5 ml 
JC-1 working solution (BD MitoScreen Kit, Becton-Dickinson) 
to each sample. Samples were incubated for 10-15 min at 37˚C 
in the dark. Mitochondrial membrane potential was measured 
using the BD FACSCanto flow cytometer (Becton-Dickinson).
Confocal microscopy. After treatment, cells were fixed with 
4% PFA, blocked with 2% bovine serum albumin, stained 
with anti-tubulin monoclonal antibody, and then with FITC 
conjugated anti-mouse IgG antibody. PI was used to stain the 
nuclei. Cells were visualized using a Leica TCS SP2 Spectral 
Confocal System.
Tubulin assays. Tubulin assembly was measured through turbi-
dimetry, as described previously (29). Assay mixtures containing 
1.0 mg/ml (10 µM) tubulin and varying drug concentrations 
were preincubated for 15 min at 30˚C in the absence of GTP. The 
samples were then placed on ice, and 0.4 mM GTP was added. 
Reaction mixtures were transferred to cuvettes held at 0˚C, and 
turbidity development was monitored for 20 min at 30˚C after a 
rapid temperature increase. Drug concentrations that inhibited 
the increase in turbidity by 50% relative to a control sample 
were determined. Inhibition of the binding of [3H]colchicine to 
tubulin was measured as described previously (29). A total of 
1.0 µM tubulin was incubated with 5.0 µM [3H]colchicine and 
5.0 µM inhibitor for 10 min at 37˚C. At this time, approximately 
40 to 60% of maximum colchicine binding occurred.
Western blot assay. The treated cells were collected and washed 
with PBS. After centrifugation, cells were lysed in a lysis buffer. 
Figure 2. Effects of HAC-Y6 in the NCI 60 human tumor cell line panel.
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The lysates were incubated on ice for 30 min and centrifuged at 
12,000 x g for 20 min. Supernatants were collected, and protein 
concentrations were then determined using the Bradford 
assay. After adding a 5X sample loading buffer containing 
625 mM Tris-HCl, pH 6.8, 500 mM dithiothreitol, 10% SDS, 
0.06% bromophenol blue, and 50% glycerol, protein samples 
were electrophoresed on 10% SDS-polyacrylamide gels and 
transferred to a nitrocellulose membrane. Immunoreactivity 
was detected using the western blot chemiluminescence 
reagent system (PerkinElmer, Boston, MA, USA). β-actin was 
used as a loading control.
Statistical analysis. Statistical analysis was performed with 
an analysis of variance (ANOVA) followed by the Tukey's test. 
All data were expressed as mean ± SD from at least three inde-
pendent experiments. *P<0.001 was indicative of a significant 
difference.
Results
Growth inhibitory activity of HAC-Y6 against a panel of 
human cancer cell lines. Evaluation of the HAC-Y6 inhibitory 
activity against the NCI panel of 60 human cancer cell lines 
provided the results shown in Fig. 2. The mean graph midpoint 
(MID) values for the log GI50, log TGI, and log LC50 values 
were -7.04, -5.26 and -4.17, respectively. For total growth 
inhibition (TGI), HAC-Y6 also demonstrated significant 
inhibitory activity (log TGI <-6.5) against 12 tumor cell lines: 
HL-60, RPMI-8228, NCI-H522, COLO 205, HCC-2998, 
HCT-116, HT29, MDA-MB-435, OVCAR-3, NCI/ADR-RES, 
PC-3 and DU145.
HAC-Y6 induces toxicity in COLO 205 cells. Exposure of 
COLO 205 cells to HAC-Y6 for 48 h and performance of MTT 
metabolism assays confirmed the effects of HAC-Y6 on cell 
viability. The IC50 value was 0.52±0.035 µM with HAC-Y6 
decreasing COLO 205 cell viability in a dose-dependent 
manner. Exposure of COLO 205 cells to 0.1, 0.25, 0.5, 0.75 
and 1 µM HAC-Y6 reduced the survival to 90.8±1.9, 69.2±0.9, 
49.4±1.7, 32.3±3.4 and 14.1±1.1% of the control (0.1% DMSO), 
respectively (Fig. 3A). HAC-Y6 inhibited COLO 205 cell 
growth dose- and time-dependently (Fig. 3B).
HAC-Y6 induces morphological changes in COLO 205 cells. 
Morphological analysis confirmed the HAC-Y6 cytotoxic 
effects. As shown in Fig. 4, apoptotic morphological changes 
included cell rounding and shrinkage after 24 h incubation 
with 0.5 µM of HAC-Y6 (the white arrowhead indicates an 
  A   B
Figure 3. Effects of HAC-Y6 on viability of COLO 205 cells. (A) COLO 205 cells were exposed to different concentrations of HAC-Y6 for 48 h. (B) COLO 205 cells 
were exposed to 0, 0.1, 0.25, 0.5, 0.75 and 1 µM HAC-Y6 for 24, 48 and 72 h, respectively. Cell viability was assessed using the MTT assay. The data are presented 
as mean ± SEM of three independent experiments. Cells without treatment served as a control. *P<0.001 vs. control.
Figure 4. HAC-Y6 induces morphological changes in COLO 205 cells. 
COLO 205 cells were treated with 0.5 µM HAC-Y6 for (B) 24, (C) 36, (D) 48, 
(E) 60  and (F) 72 h. (A) Cells without treatment served as a control. The white 
arrowhead indicates an apoptotic nucleus, and the black arrowheads indicate 
multinucleate cells. Scale bar, 20 µm.
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apoptotic nucleus). Fig. 4D and F show COLO 205 cells with 
more than one nucleus per cell (the black arrowheads indicate 
multinucleate cells).
HAC-Y6 induces apoptosis in COLO 205 cells. Staining 
COLO 205 cells with Hoechst 33258 confirmed apoptosis as 
the cause of reduced cell viability. As shown in Fig. 5, control 
cells without HAC-Y6 treatment exhibited uniformly dispersed 
chromatin, normal organelles, and intact cell membranes. Cells 
treated with 0.5 µM of HAC-Y6 for 24, 36, 48, 60 and 72 h 
demonstrated typical characteristics of apoptosis, including 
the condensation of chromatin, the shrinkage of nuclei and the 
appearance of apoptotic bodies (the white arrowhead indicates 
an apoptotic nucleus).
Annexin V-FITC/PI double-labeling detected phosphati-
dylserine externalization, a hallmark of the early phase of 
apoptosis (Fig. 6). Cells incubated in the absence of HAC-Y6 
for 12, 24, 36 and 48 h were undamaged and were negative for 
both Annexin V-FITC and PI staining (Q3). After incubation 
with 1 µM HA-Y6 for 24 to 48 h, the numbers of advanced 
apoptotic cells stained by positive Annexin V-FITC and 
Figure 5. Fluorescent images of Hoechst staining showing HAC-Y6 induced cell 
death. COLO 205 cells were treated with 0.5 µM HAC-Y6 for (B) 24, (C) 36, 
(D) 48, (E) 60 and (F) 72 h prior to Hoechst staining. (A) Cells without treatment 
served as a control. The white arrowhead indicates an apoptotic nucleus, and the 
black arrowheads indicate multinucleate cells. Scale bar, 20 µm.
Figure 6. Confirmation of HAC-Y6-induced apoptotic cell death. COLO 205 
cells were treated with HAC-Y6 for different periods of time and apoptosis 
was assessed using Annexin V/PI staining and flow cytometry. The fraction 
of Annexin V-positive COLO 205 cells was 2.9% prior to treatment and 4.3, 
10.2, 17.8 and 19.5% after treatment with HAC-Y6 for 12, 24, 36 and 48 h, 
respectively.
Figure 7. Effects of HAC-Y6 on mitochondrial membrane potential in COLO 
205 cells. Cells (1x106 cells/ml) were untreated or treated with HAC-Y6 (1 µM, 
6-24 h) to induce apoptosis. Cells were stained with JC-1 according to the 
protocol on a BDTM MitoScreen as described in Materials and methods for 
staining cells with JC-1 and analyzing by flow cytometry.
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negative PI (Q4) were significantly increased as the incubation 
time grew longer. The numbers of advanced apoptotic cells 
stained by positive Annexin V-FITC and PI (Q2) also increased 
significantly with incubation time.
During apoptosis, the mitochondrial membrane potential 
(∆ψm) decreases. Cells treated with 1 µM of HAC-Y6 for 6, 12 
and 24 h, stained cells with JC-1 confirmed apoptosis as the 
cause of decreased ∆ψm. As shown in Fig. 7, JC-1 fluorescence 
is seen in both the FL2 and FL1 channel (P2) in the control 
cell population (0 h). There is a significant increase in the 
number of cells with reduced red fluorescence (P3), indicative 
of a change in the ∆ψm, in the population induced to undergo 
apoptosis (6-24 h). These data demonstrate that HAC-Y6 
induced cell apoptosis in COLO 205 cells.
HAC-Y6 induces G2/M arrest, multinucleation and apoptosis 
in COLO 205 cells. Treatment of COLO 205 cells with 1 µM 
of HAC-Y6 for 0, 12, 24, 36, 48 and 60 h, followed by flow 
cytometric analysis to determine cell cycle distribution of the 
treated cells, was used to investigate the effects of HAC-Y6 on 
disruption of the cell cycle and provide further insights into the 
apoptotic effects of the compound. As shown in Fig. 8, HAC-Y6 
induced a time-dependent accumulation of G2/M (4N) cells, as 
well as causing formation of octoploid cell (8N) population 
and apoptotic (sub-G1) cells. These flow cytometric findings 
with HAC-Y6-treated COLO 205 cells are in accord with the 
multinucleated cells presented above (Figs. 4D, F and 5; the 
black arrowheads indicate multinucleate cells).
HAC-Y6 inhibites tubulin polymerization. COLO 205 cells 
were treated with 1 µM of HAC-Y6 for 24 h and then stained 
Figure 8. Effects of HAC-Y6 on the cell cycle in COLO 205 cells. (A) 
COLO 205 cells were incubated with 1 µM of HAC-Y6 for 0, 12, 24, 36, 48 
and 60 h, respectively. They were then harvested and analyzed using flow 
cytometry. (B) Bar graph representation of the cell cycle distribution and 
percentages of sub-G1, 4N and 8N populations.
  A
  B
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appropriately and examined in a confocal microscope to 
determine the effects of the compound on the cellular 
microtubule cytoskeleton. As shown in Fig. 9A, treatment 
with HAC-Y6 resulted in microtubule changes similar 
to those induced by colchicine. Both compounds caused 
cellular microtubule depolymerization with short micro-
tubule fragments scattered throughout the cytoplasm. 
Taxol, in contrast, induced significantly increased tubulin 
polymerization. As shown in Fig. 9B, after cells were 
treated with HAC-Y6 for 6-48 h, HAC-Y6 caused inhibi-
tion of microtubule (α- and β-tubulin) assembly. Therefore, 
our data demonstrated that HAC-Y6 induced microtubule 
depolymerization.
Further examination of HAC-Y6 in tubulin assays and 
comparison with combretastatin A-4 (CA-4) provided the 
results presented in Table I. HAC-Y6 potently inhibited tubulin 
assembly, with an IC50 value of 0.81±0.03 µM. Although 
HAC-Y6 inhibited tubulin assembly more potently than CA-4 
(IC50 1.3±0.1 µM), it was slightly less effective than CA-4 in 
inhibiting colchicine binding to tubulin.
Increased BubR1 and inhibition of aurora kinase by HAC-Y6 
associated with G2/M cell cycle arrest. Cyclin B1 and CDK1 
are markers for induction of mitotic arrest. Treatment of 
Figure 9. HAC-Y6 causes microtubule disassembly in cultured cells. 
(A) Confocal staining was performed on COLO 205 cells without treat-
ment and following treatment with 1 µM of HAC-Y6, 1 µM colchicine or 
1 µM taxol. Cells were fixed, permeabilized and stained with anti-α-tubulin 
monoclonal antibody. Cells were visualized using confocal microscopy. 
(B) HAC-Y6 decreased microtubule (α- and β-tubulin) protein expres-
sion by western blot analysis. At least three independent experiments 
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COLO 205 cells with 1 µM of HAC-Y6 increased cyclin B1 
protein levels (Fig. 10A). BubR1, an essential component of the 
mitotic check-point, localizes in kinetochores (8). Treatment 
of COLO 205 cells with 1 µM HAC-Y6 increased the levels of 
BubR1 (Fig. 10A). This result suggests that BubR1 contributed 
to activation of the mitotic checkpoint induced by HAC-Y6. 
The compound directly causes microtubule disassembly, and 
the cell cycle protein changes, including increased BubR1 
expression, are secondary to the failure to form a spindle, 
which results from disruption of tubulin assembly.
Treatment of COLO 205 cells with 1 µM HAC-Y6 was 
used to investigate the effects of HAC-Y6 on aurora kinase 
function. As shown in Fig. 10B, HAC-Y6 decreased aurora A, 
phospho-aurora A, aurora B and phospho-aurora B expres-
sion. Histone H3 is one of the substrates of aurora B kinase. 
During mitosis, aurora B is required for phosphorylation 
of histone H3 on serine 10, and this might be important 
for chromosome condensation (15). We therefore examined 
whether HAC-Y6 inhibited phosphorylation of histone H3 
in COLO 205 cells by western blot analysis. As shown in 
Fig. 10B, HAC-Y6 decreased phospho-H3 expression after 
Table I. Anti-tubulin data for HAC-Y6.
 Inhibition Inhibition of colchicine
 of tubulin binding with 5 µM
 assemblya IC50 inhibitorb %
Compound  (µM) ± SD  inhibition ± SD
CA-4 1.30±0.1 98±1
HAC-Y6 0.81±0.03 90±1
aAssembly assay contained 10 µM tubulin. bColchicine binding assay 
contained 1 µM tubulin and 5 µM [3H]colchicine.
Figure 10. HAC-Y6 increased G2/M phase checkpoint protein expression. 
COLO 205 cells were treated with 1 µM HAC-Y6 for the indicated time 
periods and lysed for protein extraction. Protein samples (40 µg protein/lane) 
were separated using 10% SDS-PAGE and subjected to immunoblot analysis 
with antibodies specific to (A) BubR1, cyclin B1, CDK1; and (B) aurora A, 
phospho-aurora A, aurora B, phospho-aurora B and phospho-H3. At least three 
independent experiments were performed obtaining similar results. β-actin 
was used as a loading control.
  A
  B
Figure 11. HAC-Y6 induces apoptotic pathways in COLO 205 cells. COLO 205 
cells were treated with 1 µM of HAC-Y6 for the indicated times and lysed 
for protein extraction. Protein samples (40 µg protein/lane) were separated 
using 10% SDS-PAGE and subjected to immunoblot analysis with antibodies 
specific to (A) PARP, caspase-3, caspase-9; and (B) cytochrome c, Apaf-1, AIF 
and Endo G. At least three independent experiments were performed obtaining 
similar results. β-actin was used as a loading control.
  A
  B
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a 6 h treatment. This finding suggests that inactivation of 
aurora kinases A and B is involved in HAC-Y6-induced 
G2/M arrest and multinucleation.
HAC-Y6 induces apoptosis via activation of mitochondrial 
signaling pathways and affects Bcl-2 family proteins in 
COLO 205 cells. Following our observations that HAC-Y6 
caused apoptosis in COLO 205 cells, we next determined levels 
of selected proteins associated with apoptosis. The activation 
of caspases is a hallmark of apoptosis. Activated caspases 
cleave a variety of target proteins including poly(ADP-ribose) 
polymerase, DNA-dependent protein kinase, and sterol regu-
latory-dependent binding protein, and thereby disable cellular 
processes and break down the cellular structure (23). To 
investigate whether HAC-Y6-induced apoptosis was involved 
in the activation of caspase cascades, COLO 205 cells were 
exposed to 1 µM of HAC-Y6 for 6, 12, 24, 36 and 48 h. The 
activities of caspase-3 and caspase-9 were then determined 
using Western blot analysis, which revealed activation of 
caspase-3 and caspase-9 within 12 h of HAC-Y6 treatment. 
Cleavage of PARP, a substrate for caspase-3, also occurred 
(Fig. 11A). HAC-Y6 also increased levels of Endo G, AIF, 
Apaf-1 and cytochrome c (Fig. 11B). These results suggest 
that the mitochondrial signaling pathways of COLO 205 cells 
mediate HAC-Y6-induced apoptosis.
The Bcl-2 family proteins are key regulators of mitochon-
drial-related apoptotic pathways (30). Some of these proteins 
(such as Bcl-2 and Bcl-xL) are anti-apoptotic, whereas others 
(such as Bad, Bax and Bid) are pro-apoptotic. The balance 
of pro- and anti-apoptotic bcl-2 proteins influences the sensi-
tivity of cells to apoptotic stimuli (31). Exposure of COLO 205 
cells to 1 µM of HAC-Y6 for 6, 12, 24, 36 and 48 h verified 
the involvement of Bcl-2 protein activity in HAC-Y6-induced 
apoptosis. As shown in Fig. 12, results indicated that HAC-Y6 
reduced anti-apoptotic Bcl-2 and Bcl-xL levels, as well as 
increased pro-apoptotic Bax levels and the release of Endo G, 
AIF, Apaf-1, cytochrome c and procaspase-9 from the mito-
chondria to the cytosol. Release of Apaf-1, and cytochrome c 
leads to the activation of caspase-9. Activated caspase-9, in 
turn, cleaves and activates caspase-3.
Discussion
Derivation of new drugs from natural products involves the 
synthesis of new compounds by modifying the structural 
skeletons of the natural products. Several reports have demon-
strated that carbazole alkaloids exhibit anticancer activity 
(24-26). α-carboline is a bioisostere of carbazole, where the 
benzene ring of carbazole is replaced by a pyridine ring, and 
previous studies have described the anticancer effects of its 
derivatives (32,33). In this study, we describe the anticancer 
mechanisms of the novel α-carboline derivative HAC-Y6.
The NCI results for HAC-Y6 presented in Fig. 2 indicated 
potent inhibitory activity against multiple cancer cell lines. 
The LC50 values, however, indicated selective inhibition of 
Figure 12. HAC-Y6 affects Bcl-2 family proteins in COLO 205 cells. 
COLO 205 cells were treated with 1 µM of HAC-Y6 for the indicated times 
and lysed for protein extraction. Protein samples (40 µg protein/lane) were 
separated using 10% SDS-PAGE and subjected to immunoblot analysis with 
antibodies specific to Bax, Bcl-xL and Bcl-2. At least three independent 
experiments were performed obtaining similar results. β-actin was used as 
a loading control.
Figure 13. The proposed model by which HAC-Y6 induces G2/M phase arrest, polyploidy and apoptosis in COLO 205 cells.
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COLO 205 and HCC 2998 colon cancer cells, with log LC50 
values of -6.3 and -5.97, respectively; potencies that are 
approximately 100 times the average value (-4.17). These 
results prompted our further investigation of the effects of the 
compound on COLO 205 cells.
Investigation of the anticancer activity of HAC-Y6 in 
COLO 205 cells provided data indicating that HAC-Y6 induced 
cytotoxicity in COLO 205 cells in a dose- and time-dependent 
manner (Fig. 3), acting through G2/M arrest, polyploidy and 
apoptosis (Fig. 8). Annexin V/PI double staining demonstrated 
the presence of apoptotic cells in HAC-Y6-treated COLO 205 
cells (Fig. 6). Mitochondrial membrane potential analysis 
showed that HAC-Y6 induced mitochondrial membrane poten-
tial in support of apoptosis in COLO 205 cells (Fig. 7).
Microtubules are important cellular targets for anticancer 
therapy, because of their key role in mitosis (34). In this study, 
HAC-Y6 induced the depolymerization of microtubules in 
COLO 205 cells. Treatment with HAC-Y6 for 24 h resulted 
in microtubule changes similar to those induced by colchicine 
(Fig. 9A). HAC-Y6 caused inhibition of microtubule (α- and 
β-tubulin) assembly (Fig. 9B). HAC-Y6 can thus be classified 
as a microtubule-depolymerizing agent.
Previous investigations have reported that cyclin B1/CDK1 
complexes are involved in the regulation of G2/M phase and 
M-phase transitions (9,35). HAC-Y6 initiated induction of G2/M 
phase arrest (4N) within 12 to 24 h and polyploidy (8N) within 
36 to 60 h of treatment (Fig. 8B). Our data showed increased 
levels of cyclin B1 after HAC-Y6 treatment (Fig. 10A). HAC-Y6 
arrested the growth of COLO 205 cells at the G2/M phase 
through the accumulation of cyclin B1. BubR1 is a key compo-
nent of the mitotic spindle checkpoint machinery (8,9). In this 
study, BubR1 upregulation caused microtubule disruption, as 
indicated by a significant increase in the percentage of cell 
cycle G2/M arrest. Results demonstrated an increase in BubR1 
after HAC-Y6 treatment (Fig. 10A). We suggest that HAC-Y6 
induced G2/M arrest and multinucleation via the accumulation 
of BubR1 protein.
Aurora kinases play important roles in chromosome align-
ment, segregation and cytokinesis during mitosis (14,17,36). 
Our data showed decreased aurora A, phospho-aurora A, 
aurora B, phospho-aurora B and phospho-H3 expression after 
HAC-Y6 treatment (Fig. 10B). HAC-Y6, therefore, arrested the 
growth of COLO 205 cells at the G2/M phase and induced 
polyploidy through the inactivation of aurora kinases.
Apoptosis regulators provide the basis for novel thera-
peutic strategies aimed at promoting tumor cell death (21,37). 
Mitochondria and Bcl-2 largely control intrinsic pro-apoptotic 
pathways. When mitochondria receive an apoptotic signal, 
their outer membranes become permeabilized, releasing 
Endo G, AIF, Apaf-1, cytochrome c and procaspase-9, and 
into the cytosol and activating caspase-3 through caspase-9, 
leading to apoptosis (38-40). Our data showed that these 
effects occurred after HAC-Y6 treatment (Fig. 11). Proteolytic 
degradation of PARP further demonstrated the involvement 
of caspase activation. These findings together suggest that 
HAC-Y6 might activate intrinsic signaling pathways.
The Bcl-2 family proteins largely mediate the mitochon-
drial apoptotic pathway (41,42). Overexpression of Bcl-2 
increases cell survival by suppressing apoptosis. Bax levels 
increase in conjunction with Bax inhibition of Bcl-2, and the 
cells undergo apoptosis. The present results showed increased 
Bax 6 h after HAC-Y6 treatment and decreased Bcl-xL 
and Bcl-2 12 h after HAC-Y6 treatment (Fig. 12). HAC-Y6, 
therefore, induced apoptosis of COLO 205 cells through Bax 
activation and Bcl-xL and Bcl-2 inactivation.
Among our findings, HAC-Y6 significantly decreased 
levels of HSP90 in COLO 205 cells after a 2 h treatment (data 
not shown). HSP90 plays an essential role as a molecular chap-
erone for stress-accumulated misfolded proteins to prevent 
their aggregation (7,43,44).
Fig. 13 summarizes the molecular signaling pathways 
induced by HAC-Y6. We demonstrated that HAC-Y6, a novel 
synthetic HSP90 inhibitor, exerts potent anticancer activity 
against COLO 205 cells through microtubule depolymeriza-
tion, BubR1 activation, aurora A and aurora B inactivation, 
induction of G2/M arrest and polyploidy. HAC-Y6 also 
induces apoptosis of COLO 205 cells via intrinsic signaling 
pathways. These findings suggest that HAC-Y6 has potential 
use as a novel therapeutic agent for the treatment of human 
colon carcinoma.
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